We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+17.28%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$11B
AUM Growth
+$1.48B
Cap. Flow
-$1.03B
Cap. Flow %
-9.36%
Top 10 Hldgs %
83.4%
Holding
140
New
7
Increased
14
Reduced
16
Closed
6

Top Buys

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$55.6M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$44.2M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$40.8M
4
NGNE icon
Neurogene
NGNE
+$28.1M
5
EXEL icon
Exelixis
EXEL
+$25.4M

Top Sells

Rank Stock Value
1
XNPT
XENOPORT, INC.
XNPT
+$24.5M
2
MDVN
MEDIVATION, INC.
MDVN
+$19.9M
3
NVAX icon
Novavax
NVAX
+$17.3M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$16.2M
5
INSM icon
Insmed
INSM
+$13.8M

Sector Composition

Rank Sector Weight
1 Healthcare 82.76%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLRN
101
DELISTED
Acceleron Pharma
XLRN
$1.04M 0.01%
28,765
– –
FPRX
102
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$1.01M 0.01%
19,247
– –
TENX icon
103
Tenax Therapeutics
TENX
$410M
$972K 0.01%
13
– –
SVRA icon
104
Savara
SVRA
$1.09B
$944K 0.01%
122,629
+67,371
+122% +$1.91M
APTO
105
DELISTED
Aptose Biosciences, Inc.
APTO
$909K 0.01%
+898
New +$934K
INFI
106
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$905K 0.01%
+580,400
New +$892K
DVAX
107
DELISTED
Dynavax Technologies
DVAX
$787K 0.01%
75,000
– –
ALNY icon
108
Alnylam Pharmaceuticals
ALNY
$38.2B
$769K 0.01%
11,340
– –
MDGL icon
109
Madrigal Pharmaceuticals
MDGL
$12.7B
$732K 0.01%
57,762
-2
-0% -$19
ADAP
110
DELISTED
Adaptimmune Therapeutics
ADAP
$705K 0.01%
100,000
– –
AIXC
111
AIxCrypto Holdings Inc
AIXC
$13.7M
$672K 0.01%
3
– –
WINT
112
DELISTED
Windtree Therapeutics Inc
WINT
$653K 0.01%
254,973
– –
CMRX
113
DELISTED
Chimerix, Inc.
CMRX
$638K 0.01%
115,216
– –
ABUS icon
114
Arbutus Biopharma
ABUS
$861M
$621K 0.01%
180,582
– –
ABEO icon
115
Abeona Therapeutics
ABEO
$353M
$610K 0.01%
+4,067
New +$398K
BDSI
116
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$567K 0.01%
210,021
– –
FMI
117
DELISTED
Foundation Medicine, Inc.
FMI
$488K ﹤0.01%
20,892
– –
AKAO
118
DELISTED
Achaogen Inc
AKAO
$479K ﹤0.01%
100,000
– –
CYTR
119
DELISTED
CytRx Corp
CYTR
$388K ﹤0.01%
109,999
– –
SRRA
120
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$364K ﹤0.01%
5,000
– –
LJPC
121
DELISTED
La Jolla Pharmaceutical Company
LJPC
$327K ﹤0.01%
13,746
– –
CCXI
122
DELISTED
ChemoCentryx, Inc.
CCXI
$296K ﹤0.01%
49,064
– –
BGMSP
123
DELISTED
Bio Green Med Solution Inc Preferred Stock
BGMSP
$90K ﹤0.01%
13,253
– –
BTX.WS
124
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
$17K ﹤0.01%
20,084
– –
AUPH icon
125
Aurinia Pharmaceuticals
AUPH
$1.97B
– –
-711,499
Closed -$2.12M
2 3 4
5
6

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2016 Portfolio in Review

As of Q3 2016, Baker Bros. Advisors held 140 positions worth $11B, up 16% from $9.54B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Baker Bros. Advisors withdrew a net $1.03B in Q3 2016, closing 6 positions and reducing 16 holdings. Its most notable exit was XENOPORT, INC., an estimated $24.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 81% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in ContraFect Corporation worth $10M.

  • Baker Bros. Advisors's largest Q3 2016 buy was ContraFect Corporation: 5,057 shares worth $10M.
  • Baker Bros. Advisors added most to Amarin Corp in Q3 2016, an estimated $55.6M increase.
  • Baker Bros. Advisors's biggest Q3 2016 reduction was BioCryst Pharmaceuticals, cutting an estimated $16.2M.
  • Baker Bros. Advisors fully exited XENOPORT, INC. in Q3 2016, selling an estimated $24.5M.
  • Baker Bros. Advisors's ten largest holdings make up 83% of its $11B portfolio in Q3 2016.
  • Baker Bros. Advisors opened 7 new positions and closed 6 in Q3 2016.
  • Baker Bros. Advisors's portfolio value rose 16% quarter-over-quarter to $11B.

Based on Baker Bros. Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.